Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

NCT07614191 is registered in ClinicalTrials.gov with Vivacta Biotechnology (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07614191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07614191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases
Lead sponsor
Vivacta Biotechnology (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 25, 2026
Completion date
December 30, 2031
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe refractory autoimmune diseases